Safety and Activity of the Highly Specific BTK Inhibitor BGB-3111 in Combination with the PD-1 Inhibitor BGB-A317 in Patients with B-Cell Lymphoid Malignancies

被引：0

作者：

Cull, Gavin

Opat, Stephen

Trotman, Judith

Hilger, James

Zhang, Xiaoping

Feng, Shibao

Ro, Sunhee

Huang, Jane

Tam, Constantine S.

机构：

来源：

BLOOD | 2017年 / 130卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4057

引用

页数：4

共 50 条

[41] Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies [J].

Roberts, Andrew W. ;

Advani, Ranjana H. ;

Kahl, Brad S. ;

Persky, Daniel ;

Sweetenham, John W. ;

Carney, Dennis A. ;

Yang, Jianning ;

Busman, Todd B. ;

Enschede, Sari H. ;

Humerickhouse, Roderick A. ;

Seymour, John F. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (05) :669-678

[42] Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study [J].

Wierda, William G. ;

Shah, Nirav N. ;

Cheah, Chan Y. ;

Lewis, David ;

Hoffmann, Marc S. ;

Coombs, Catherine C. ;

Lamanna, Nicole ;

Ma, Shuo ;

Jagadeesh, Deepa ;

Munir, Talha ;

Wang, Yucai ;

Eyre, Toby A. ;

Rhodes, Joanna M. ;

McKinney, Matthew ;

Lech-Maranda, Ewa ;

Tam, Constantine S. ;

Jurczak, Wojciech ;

Izutsu, Koji ;

Alencar, Alvaro J. ;

Patel, Manish R. ;

Seymour, John F. ;

Woyach, Jennifer A. ;

Thompson, Philip A. ;

Abada, Paolo B. ;

Ho, Caleb ;

McNeely, Samuel C. ;

Marella, Narasimha ;

Nguyen, Bastien ;

Wang, Chunxiao ;

Ruppert, Amy S. ;

Nair, Binoj ;

Liu, Hui ;

Tsai, Donald E. ;

Roeker, Lindsey E. ;

Ghia, Paolo .

LANCET HAEMATOLOGY, 2024, 11 (09) :e682-e692

[43] A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies [J].

Cheson, Bruce D. ;

Shouse, Geoffrey P. ;

Assouline, Sarit ;

Lewis, Katharine L. ;

Hawkes, Eliza A. ;

Munir, Talha ;

Davies, Andrew S. ;

Langerbeins, Petra ;

Tam, Constantine S. ;

Gregory, Gareth P. ;

Choi, Michael Y. ;

Sun, William ;

Atwal, Siminder K. ;

Hong, Wan-Jen ;

Sarkozy, Clementine .

BLOOD, 2023, 142

[44] Preliminary Results from a Phase 1b Study of Non-Covalent Pan-Mutant BTK Inhibitor Docirbrutinib (AS-1763) in Patients with Previously Treated B-Cell Malignancies [J].

Jain, Nitin ;

Coombs, Catherine C. ;

D'Olimpio, James ;

Shah, Nirav N. ;

Barrientos, Jacqueline C. ;

Lee, Seung Tae ;

Gillis-Smith, Andrew ;

Ma, Shuo ;

Kirita, Shirou ;

Sawa, Masaaki ;

Miyamoto, Kyoko ;

Arimura, Akinori ;

Wierda, William G. ;

Gandhi, Varsha ;

Pinilla-Ibarz, Javier .

BLOOD, 2024, 144 :1866-1867

[45] A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenstrom Macroglobulinemia (WM): Preliminary Data [J].

Soumerai, Jacob D. ;

Lasica, Masa ;

Opat, Stephen ;

Cheah, Chan Y. ;

Chan, Henry ;

Verner, Emma ;

Barca, Eva Gonzalez ;

Tedeschi, Alessandra ;

Hilger, James ;

Fang, Yiqian ;

Simpson, David ;

Tam, Constantine S. .

BLOOD, 2022, 140 :9325-9327

[46] Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis [J].

Zhao, Huimin ;

Huang, Shanshan ;

Wu, Jianyu ;

Lu, Yanlan ;

Zou, Yue ;

Zeng, Haijian ;

Li, Chunlan ;

Wang, Jin ;

Zhang, Xiaochen ;

Duan, Siliang ;

Liang, Weiming .

FRONTIERS IN IMMUNOLOGY, 2025, 16

[47] A phase 1 study evaluating PRT2527, a potent and highly selective CDK9 inhibitor, in patients with select relapsed/refractory B-cell malignancies [J].

Cheson, Bruce ;

Assouline, Sarit ;

Munir, Talha ;

Langerbeins, Petra ;

Tam, Constantine S. ;

Gregory, Gareth ;

Morschhauser, Franck ;

Jurczak, Wojciech ;

Choi, Michael ;

Shouse, Geoffrey ;

Tani, Monica ;

Paris, Gina ;

Sun, William ;

Atwal, Siminder ;

Hong, Wan-Jen ;

Sarkozy, Clementine .

LEUKEMIA & LYMPHOMA, 2023, 64 :S48-S48

[48] A PHASE 1 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES TREATED WITH A PI3K DELTA INHIBITOR (INCB040093) ALONE OR IN COMBINATION WITH A SELECTIVE JAK1 INHIBITOR (INCB039110) [J].

Phillips, T. ;

Forero-Torres, A. ;

Sher, T. ;

Diefenbach, C. ;

Talpaz, M. ;

Scherle, P. ;

Schaub, R. ;

Zhou, L. ;

Pulini, J. ;

Leopold, L. ;

Spear, M. ;

Barr, P. .

HAEMATOLOGICA, 2015, 100 :110-110

[49] Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity [J].

Flinn, Ian ;

Hamlin, Paul A. ;

Strickland, Donald K. ;

Pandey, Anjali ;

Birrell, Matt ;

Coffey, Greg ;

Leeds, Janet ;

Curnutte, John T. ;

Burger, Jan Andreas ;

Wagner-Johnston, Nina D. ;

Patel, Manish R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

[50] Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor [J].

Mato, Anthony R. ;

Flinn, Ian W. ;

Pagel, John M. ;

Brown, Jennifer R. ;

Cheah, Chan Y. ;

Coombs, Catherine C. ;

Patel, Manish R. ;

Rothenberg, S. Michael ;

Tsai, Donald E. ;

Ku, Nora C. ;

Wang, Michael L. .

BLOOD, 2019, 134

← 1 2 3 4 5 →